About Gordon Ringold
Gordon Ringold is an executive chairman of the board at Maxymune Therapeutics.
Gordon Ringold reports to the SEC as a director or major shareholder of 4 public companies, including Apexigen (APGN), Ardelyx (ARDX) and Alexza Pharmaceuticals (ALXA).
Gordon Ringold first appears on SEC filings in 2006.
Experience
This experience comes from Gordon Ringold's profile and from SEC filings. For roles taken from filings, the years are when the filings name Gordon Ringold in the role, so the role may have started earlier or lasted longer.
SB
Salsa Biotherapeutics Current
Co-founder; Sr. Advisor
2025 – Present
Maxymune Therapeutics, Inc. Current
Executive Chairman of the Board
Founder (2023 – Present)
2023 – Present · Los Altos, CA
Develops treatments for people with immune system disorders.
QB
Quadriga Biosciences Current
Chief Executive Officer
2015 – Present
OI
Okava Pharmaceuticals, Inc.
Member Board Of Directors
2017 – 2026
AI
Apexigen, Inc.
Director
2022 – 2023 · Public company (APGN)
AI
Ardelyx, Inc.
Director
2014 – 2020 · Public company (ARDX)
AI
Alexza Pharmaceuticals Inc.
Founder (2002 – 2016)
Director
2002 – 2016 · Public company (ALXA)
SA
SurroMed and Alavita
Chief Executive
2000 – 2013
MI
Maxygen Inc.
Director and 10% owner
Co-Founder (1996 – 2013)
1996 – 2013 · Public company (MAXY)
AF
Affymax
President
1991 – 2000
SY
Syntex
Director of Cancer Biology
1986 – 1991
SM
Stanford University School of Medicine
Faculty
1978 – 1987
Key Colleagues at Startups
The people Gordon Ringold works with at each company, as listed on that company's latest Form D.
Maxymune Therapeutics, Inc. · Form D/A, Jun 3, 2026
Tatjana Naranda
President, Chief Operating Officer and director
Neil Solomons
Director